TY - JOUR
T1 - Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
AU - Choon, Siew Eng
AU - Lebwohl, Mark G.
AU - Turki, Hamida
AU - Zheng, Min
AU - Burden, A. David
AU - Li, Ling
AU - Quaresma, Manuel
AU - Thoma, Christian
AU - Bachelez, Hervé
N1 - Funding Information:
The study was supported and funded by Boehringer Ingelheim. Isabella Goldsbrough, PhD, of Open Health Communications (London, UK), provided writing, editorial, and formatting support, which was contracted by Boehringer Ingelheim.
Publisher Copyright:
© 2023 S. Karger AG. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - Background: Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options. Objective: The aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial. Methods: Investigators collected retrospective medical data characterizing patients' GPP flares prior to clinical trial enrollment. Data on overall historical flares were collected, as well as information on patients' typical, most severe, and longest past flares. This included data on systemic symptoms, flare duration, treatment, hospitalization, and time to clearance of skin lesions. Results: In this cohort (N = 53), patients with GPP experienced a mean of 3.4 flares per year. Flares were painful, associated with systemic symptoms, and often triggered by stress, infections, or treatment withdrawal. Resolution of flares was longer than 3 weeks in 57.1%, 71.0%, and 85.7% of documented (or identified) typical, most severe, and longest flares, respectively. GPP flares led to patient hospitalization in 35.1%, 74.2%, and 64.3% of patients for their typical, most severe, and longest flares, respectively. For the majority of patients, pustules took up to 2 weeks to clear for a typical flare and 3-8 weeks to clear for the most severe and longest flares. Conclusion: Our findings highlight that current treatment options are slow to control GPP flares and provide context for assessing the efficacy of new therapeutic strategies in patients with a GPP flare.
AB - Background: Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options. Objective: The aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial. Methods: Investigators collected retrospective medical data characterizing patients' GPP flares prior to clinical trial enrollment. Data on overall historical flares were collected, as well as information on patients' typical, most severe, and longest past flares. This included data on systemic symptoms, flare duration, treatment, hospitalization, and time to clearance of skin lesions. Results: In this cohort (N = 53), patients with GPP experienced a mean of 3.4 flares per year. Flares were painful, associated with systemic symptoms, and often triggered by stress, infections, or treatment withdrawal. Resolution of flares was longer than 3 weeks in 57.1%, 71.0%, and 85.7% of documented (or identified) typical, most severe, and longest flares, respectively. GPP flares led to patient hospitalization in 35.1%, 74.2%, and 64.3% of patients for their typical, most severe, and longest flares, respectively. For the majority of patients, pustules took up to 2 weeks to clear for a typical flare and 3-8 weeks to clear for the most severe and longest flares. Conclusion: Our findings highlight that current treatment options are slow to control GPP flares and provide context for assessing the efficacy of new therapeutic strategies in patients with a GPP flare.
KW - Clinical research
KW - Clinical trial
KW - Generalized pustular psoriasis
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85163208505&partnerID=8YFLogxK
U2 - 10.1159/000529274
DO - 10.1159/000529274
M3 - Article
C2 - 36796336
AN - SCOPUS:85163208505
SN - 1018-8665
VL - 239
SP - 345
EP - 354
JO - Dermatology
JF - Dermatology
IS - 3
ER -